# About RX MT2 — Melanotan 2 Research Digest Editorial Mission

> RX MT2 is an independent editorial project summarizing the peer-reviewed Melanotan 2 research literature. Not a clinic. Not a vendor. Editorial commentary on publicly available science.

## About This Site

RX MT2 is an independent editorial project that publishes summaries of the peer-reviewed research literature on Melanotan 2 (MT-II). The compound's research record spans four decades: tanning pharmacology, erectile function trials, central appetite circuitry, neuroprotection, and an expanding pharmacovigilance record. This site organizes and summarizes that record in plain language, with every quantitative claim traced to its source.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier 'RX' in the site name reflects an editorial stance — positioning this site as a reading room for the research, not as a pharmaceutical service. No prescription services, treatment consultations, or clinical recommendations are offered here.

## What This Site Covers

The Melanotan 2 literature is scientifically interesting for reasons beyond the compound's most publicized application. The serendipitous discovery that an alpha-MSH analog could produce erections in human subjects — documented in Hadley's 2005 historical account [18] — initiated a research program in central melanocortin pharmacology that ultimately contributed to the development of bremelanotide (PT-141), the first approved drug for hypoactive sexual desire disorder in premenopausal women.

This site covers the Melanotan 2 mechanism of action, the clinical trial record, MT2 dosage protocols studied in research, Melanotan 2 side effects documented in studies, and frequently asked questions. The published references list every source cited across the site.

## Editorial Standards

Every quantitative claim on this site is attributed to a specific citation in the references list. No finding is presented without a source. Where the research record is sparse or conflicting, we note it. Where adverse events are documented only in case reports and not confirmed in controlled trials, we say so.

The compound described here — MT-II — is not approved for human use by any regulatory authority. We do not describe it as safe. We do not recommend doses.

## References

[18] Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. https://pubmed.ncbi.nlm.nih.gov/15996790/

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.